Anticoag.net on Twitter: "Compass trial stopped early after rivaroxaban found effective at secondary prophylaxis of cardiovascular events. https://t.co/K0JyHKuJpV" / X
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
Large NOAC trial stopped early as primary endpoint was reached ahead of time - PACE-CME
Outcomes of the COMPASS Trial | Radcliffe Cardiology
COMPASS Trial: Inclusion and Main Exclusion Criteria and Study Design | Radcliffe Cardiology
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios | SpringerLink
Large NOAC trial stopped early as primary endpoint was reached ahead of time - PACE-CME
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial - ScienceDirect
Stroke Outcomes in the COMPASS Trial | Circulation
COMPASS Study Hub – EUROSURG STUDENTS RESEARCH COLLABORATIVE
Counseling & Therapy Des Moines, IA | TMS Procedure | Compass Clinical Associates
External applicability of the COMPASS trial – LVTS UMRS1148 INSERM UP Cité USPN
Treatment-resistant depression (TRD)
COMPASS study design. Note: Reproduced from Silberstein S, Winner PK,... | Download Scientific Diagram
COMPASS Trial Insights into Aspirin and Rivaroxaban Combined Therapy, October 13 2017 - YouTube
NEJM Journal Watch on Twitter: "The COMPASS trial: This week's @NEJM #VisualAbstract gives a recap. Read the full Original Article: https://t.co/uAjByYItsh https://t.co/SsQfo5iYnb" / X
Study design of COMPASS. To assess the safety and efficacy of... | Download Scientific Diagram
The COMPASS Trial | Circulation
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial - ScienceDirect
COMPASS - Research Studies - PHRI - Population Health Research Institute of Canada
COMPASS - ASA + rivaroxaban (or riva alone) vs ASA alone in stable CVD — NERDCAT
COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI | tctmd.com
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM
The COMPASS Trial | Circulation
